Nigeria’s biomedical lag stems from colonial legacy, brain drain, and global R&D inequity—how to rebuild trust in science as a public good
Original framing: “Nigeria needs biomedical research centres, sustainable funding – Prof Otuechere” — bing news
The ‘trickster’ here is the **patent system itself**—a seemingly neutral framework that, in Nigeria’s context, functions like the Yoruba trickster god *Eshu*, who exposes contradictions by playing both sides. On one hand, patents are framed as incentives for innovation; on the other, they lock African knowledge into Western hands, just as Eshu might ‘help’ a thief cross a river only to demand a price. The absurdity deepens when you consider that Nigeria’s *National Drug Policy (2017)* mandates local production of 40% of essential medicines, yet the same policy allows multinational pharma to patent drugs derived from Nigerian biodiversity (e.g., *Pfizer’s* patent on a compound found in Nigerian *bitter leaf*). The trickster reading reveals that the ‘gap’ in biomedical research isn’t a tragedy—it’s a feature of a system designed to keep Africa dependent. The solution? A *reverse trickster move*: use the patent system’s own rules against it, as South Africa did in 2001 by declaring a ‘public health emergency’ to bypass HIV drug patents.
Nigeria’s biomedical research crisis isn’t a technical failure—it’s the predictable outcome of a system designed to extract African knowledge while denying sovereignty over its application.
The colonial legacy isn’t just historical; it’s *active*, manifesting today in patent regimes that treat Nigerian biodiversity as a resource to be mined, not a heritage to be stewarded. The trickster reading exposes the absurdity of calling for ‘collaboration’ among scientists while the structural barriers (brain drain, aid conditionality, IP theft) remain untouched—like Eshu laughing as both sides of the same coin. The solution lies in three radical moves: (1) **Epistemic decolonization**—treating traditional and biomedical knowledge as equal partners, not hierarchies; (2) **Economic sovereignty**—using tools like the *Patent Poison Pill* to redistribute the wealth generated from African resources; and (3) **Cultural reimagination**—framing research as a collective ritual (à la *Ubuntu*) rather than a competitive race. The precedents exist: Cuba’s biomedical sovereignty, Bolivia’s *Rights of Mother Earth*, and South Africa’s HIV patent battles prove that the ‘gap’ isn’t inevitable—it’s a choice, enforced by power. Nigeria’s path forward requires naming that power, then dismantling it from within its own frameworks.